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Abstract
Background Gain of chromosome 20q is an important factor in
the progression from colorectal adenomas to carcinomas. Genes
that drive 20q gain are expected to show correlation of mRNA
and protein expression levels with 20q DNA copy number status
while functionally influencing cancer processes.CSE1L,DIDO1
andRBM39 are located on the 20q amplicon and affect processes
such as cell viability and anchorage-independent growth in
colorectal cancer. This study aimed to investigate whether
CSE1L, DIDO1 and RBM39 may drive 20q amplification.
Methods Protein expression levels were examined by immu-
nohistochemical evaluation of tissue microarrays containing a
series of colorectal adenoma and carcinoma samples, which
were characterized by genome-wide (microarray-based) DNA
and mRNA profiling.
Results CSE1L, DIDO1 and RBM39 mRNA expression
levels correlated with chromosome 20q DNA copy number
status. CSE1L protein expression was not associated with
20q gain, although its expression was increased in carcino-
mas compared to adenomas. DIDO1 and RBM39 protein
expression was quite strong in the majority of tumors irre-
spective of 20q DNA copy number status.
Conclusion The lack of correlation between protein expres-
sion levels and 20q DNA copy number status implies that
CSE1L,DIDO1 and RBM39 are merely passengers rather than
drivers of chromosome 20q gain in colorectal adenoma-to-
carcinoma progression.
Keywords Colorectal adenoma-to-carcinoma progression .
Chromosome 20q gain .CSE1L .DIDO1 . RBM39 . Driver
genes
1 Introduction
Colorectal cancer (CRC) is the second cause of cancer
related deaths in the western world [1]. Worldwide CRC
accounts for 600,000 deaths annually. CRC development
from normal colon epithelium is initiated by disruption of
the WNT signalling pathway which gives rise to benign
precursor lesions, i.e. adenomas. Colorectal adenomas can
progress into CRC, which is estimated to take place in about
5 % of cases [2]. CRC carcinogenesis is driven by multiple
genetic alterations, which accumulate in a developing tumor
upon introduction of genomic instability. Microsatellite in-
stability (MSI) is caused by failure of the DNA mismatch
repair system and leads to accumulation of DNA mutations
in approximately 15 % of CRCs. Chromosomal instability
Electronic supplementary material The online version of this article
(doi:10.1007/s13402-012-0088-2) contains supplementary material,
which is available to authorized users.
A. H. Sillars-Hardebol : B. Carvalho :R. J. A. Fijneman (*)
Department of Pathology, VU University Medical Center,
CCA1.08, PO Box 7057, 1007 MB Amsterdam, The Netherlands
e-mail: rja.fijneman@vumc.nl
J. A. Beliën :M. de Wit : P. M. Delis-van Diemen :M. Tijssen :
G. A. Meijer
Department of Pathology, VU University Medical Center,
PO Box 7057, 1007 MB Amsterdam, The Netherlands
M. A. van de Wiel
Department of Epidemiology and Biostatistics,
VU University Medical Center,
Amsterdam, The Netherlands
M. A. van de Wiel
Department of Mathematics, VU University,
Amsterdam, The Netherlands
F. Pontén
Department of Genetics and Pathology, The Rudbeck Laboratory,
Uppsala University,
Uppsala, Sweden
Cell Oncol. (2012) 35:293–300
DOI 10.1007/s13402-012-0088-2
(CIN) is observed in the majority of CRCs (about 85%) and is
characterized by gains and losses of chromosomal regions.
These gross aberrations lead to deletion or amplification of
tumor suppressor genes, oncogenes, and/or noncoding RNAs
such as miRNAs, resulting in aberrant expression of genes
that affect cancer-related biological processes [3–5].
Gain of chromosomal region 20q is frequent in CRC; it is
present in more than 60 % of carcinomas [6, 7]. Several
functional consequences of chromosome 20q gain have
been reported; 20q gain has been associated with colorectal
adenoma-to-carcinoma progression [7] and it correlates with
poor prognosis in CRC patients [8]. Usually, large frag-
ments of the 20q arm are amplified as a whole, suggesting
a role of multiple 20q genes on CRC progression. Recently,
we confirmed by functional analyses that multiple genes on
chromosome 20q contribute to cancer processes [9].
AURKA and TPX2 were identified as genes that promote
20q gain-driven colorectal adenoma-to-carcinoma progres-
sion. However, other genes located on 20q also contributed
to cancer-related processes, including CSE1L, DIDO1 and
RBM39. CSE1L and RBM39 affect cell viability while
CSE1L and DIDO1 contribute to anchorage-independent
growth (Suppl. Fig. 1) [9]. Therefore, these genes may be
drivers of 20q gain associated tumor progression.
Chromosomal regions that frequently show increased copy
numbers in tumors are believed to drive carcinogenesis by
affecting mRNA and protein expression levels of relevant
‘driver’ genes. Therefore, genes whose mRNA and protein
expression is influenced by its DNA copy number status are
candidate genes that may drive the gain of the amplicon. From
previous studies it is known that increased mRNA expression
of genes located on amplified regions is rare [7, 10]. The aim
of the present study was to investigate whether CSE1L, DI-
DO1 and RBM39 are drivers or merely passengers of 20q
gain-driven colorectal adenoma-to-carcinoma progression, by
investigation of mRNA and protein expression levels of these
genes in colorectal adenomas and carcinomas in relation to
chromosome 20q DNA copy number status.
2 Materials and methods
2.1 Correlation of mRNA expression data to DNA copy
number status
Data on DNA copy number ratio of the actual gene locus
and mRNA expression in colorectal adenomas and carcino-
mas have been previously obtained by array CGH (compar-
ative genomic hybridization) and mRNA expression
microarrays, respectively [7]. Copy number ratios of the
actual gene loci were determined by taking the tumor to
normal DNA copy number ratio of the BAC (bacterial
artificial chromosome) clone that covers the gene locus
(e.g. RP1-155G6 for CSE1L, RP4-563E14 for DIDO1 and
RP11-353C18 for RBM39). The smoothened, but not called,
ratio was used as a continuous variable. Differences in DNA
copy number ratio and mRNA expression levels between
adenomas and carcinomas and differences between tumors
with and without 20q gain were assessed by the Mann–
Whitney test. Correlation of array CGH and mRNA expres-
sion data was evaluated by Pearson correlation.
2.2 Colorectal adenoma and carcinoma tissue microarrays
Tissue microarrays had been constructed using a series of 82
colon adenomas and 82 CRCs that were collected retrospec-
tively from 2001 to 2008 at the VU University medical
center, Amsterdam, The Netherlands. All tissues were used
in compliance with the institutional ethical regulations for
use of patient material, in agreement with the “Code for
Proper Secondary Use of Human Tissue in the Netherlands”.
Tumors were characterized for MSI-status and chromosome
20q DNA copy number status as described previously [11].
Histological and molecular characteristics of the tumors are
summarized in Suppl. Table 1.
2.3 CSE1L, DIDO1 and RBM39 immunohistochemistry
Immunohistochemical stainings of CSE1L, DIDO1 and RBM39
were performedon tissuemicroarrays. Paraffin sections (4μm)were
deparaffinized in xylene and rehydrated through a series of graded
alcohol to water. Endogenous peroxidase was blocked for 30 min
with hydrogen peroxide (0.3%H2O2 inmethanol). Antigen retriev-
al was performed by autoclave heating in 10 mM citrate buffer (pH
6.0). Stainings were performed using CSE1L antibody (NCL-CAS,
mouse monoclonal, Novocastra, Newcastle upon Tyne, UK) in a
1:30 dilution, DIDO1 antibody (sc-25264, mouse monoclonal,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) in a 1:100
dilution and RBM39 antibody (rabbit polyclonal, HPA001591,
AtlasAntibodies in a 1:75 dilution. The HPA001591 antibody was
specifically generated and used for protein profiling as part of the
Human Protein Atlas project (http://www.proteinatlas.org) [12, 13].
All primary antibodies were incubated for 30 min at room temper-
ature. Stainings were subsequently detected by HRP-coupled poly-
mer (ThermoScientific, Warm Springs, Fremont, CA, USA) and
visualized by diaminbenzidine plus (DABPlus) (ThermoScientific).
Sections were counterstained with Mayer’s haematoxylin. Incuba-
tion without primary antibody was used as negative control.
2.4 Evaluation of protein expression and correlation to DNA
copy number status
Protein expression of CSE1L, DIDO1 and RBM39 was
evaluated based on staining intensity in epithelial cells and
scored as weak, moderate or strong. Per tumor the maximum
score of the evaluated cores was determined. For statistical
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analysis of protein expression, tumors were classified into two
groups based on the maximum staining score; weak and
moderate staining versus strong staining. The Chi-Square test
was used to compare protein expression between adenomas
and carcinomas and tumors with and without 20q gain. All
statistical analyses were performed in SPSS (version 15.0 for
Windows, SPSS, Chicago, Illinois, USA).
3 Results
3.1 Correlation of CSE1L, DIDO1 and RBM39 mRNA
expression with (20q) DNA copy number and adenoma/
carcinoma status
To investigate whether CSE1L, DIDO1 and RBM39 may
contribute to chromosome 20q gain-driven colorectal
adenoma-to-carcinoma progression, correlation analyses
were performed to examine the relationship between their
DNA copy number status and mRNA expression levels.
Significant correlations between DNA copy number ratios
and mRNA expression levels were observed for CSE1L (R0
0.49 with p00.0001; Fig. 1a), DIDO1 (R00.53 with p0
0.00002; Fig. 1b) and RBM39 (R00.45 with p00.0003;
Fig. 1c). Next, CSE1L, DIDO1 and RBM39 mRNA
expression levels were examined in relation to chromosome
20q gain status within the group of chromosomal instable
tumors. For this purpose, MSI tumors were excluded from
further analysis upon which the remaining colorectal tumors
(26 adenomas and 23 carcinomas) were classified into two
categories based on absence or presence of 20q gain. Mes-
senger RNA expression levels were significantly increased
in tumors with 20q gain compared to tumors without 20q
gain for each of these genes, i.e. CSE1L (p00.01; Fig. 1d),
DIDO1 (p00.001; Fig. 1e) and RBM39 (p00.001; Fig. 1f).
Genes that are functionally relevant for tumor progression
are likely to show increased mRNA expression levels in car-
cinomas compared to adenomas. As such, the fact that chro-
mosome 20q gain is associated with colorectal adenoma-to-
carcinoma progression prompted us to examine whether in-
creased CSE1L, DIDO1 and RBM39mRNA expression levels
are merely associated with tumor progression or truly driven
by chromosome 20q DNA copy number status. For each of
these genes, the difference in median mRNA expression levels
(arbitrary units) of tumors with 20q gain versus those without
20q gain (Fig. 1d-1f; CSE1L: 0.55, DIDO: 0.47, RBM39:
0.60) was larger than the difference in their median expression
levels (arbitrary units) between those adenomas and carcino-
mas for which 20q status was known (n049) (Fig. 1g-i;
CSE1L: 0.44, DIDO: 0.40, RBM39: 0.31). Results comparing
Fig. 1 Correlation of CSE1L,
DIDO1 and RBM39 mRNA
expression with (20q) DNA
copy number and adenoma/
carcinoma status. Correlation of
DNA copy number with mRNA
expression for CSE1L a,
DIDO1 b and RBM39 c. DNA
copy numbers were determined
by the copy number ratio of the
BAC covering the gene locus.
Pearson correlation coefficients
and p-values are shown. Lines
represent a linear regression fit
with 95 % confidence intervals.
CSE1L d, DIDO1 e and RBM39
f mRNA expression levels
(arbitrary units) in tumors
(n049) without and with 20q
gain. P-values were determined
by the Mann–Whitney test.
CSE1L g, DIDO1 h and RBM39
i mRNA expression levels
(arbitrary units) in adenomas
and carcinomas for which 20q
status was known (n049).
P-values were determined by
the Mann–Whitney test
CSE1L, DIDO1 and RBM39 in colorectal tumor progression 295
adenomas to carcinomas obtained for the whole data set of 37
adenomas and 31 carcinomas for which mRNA expression
data was available are shown in Suppl. Fig. 2. In fact, only the
mRNA expression level of CSE1L (p00.02 and DIDO1 (p0
0.004) remained significantly elevated in CRCs compared to
adenomas. These data indicate that the mRNA expression
levels of CSE1L, DIDO1 and RBM39 are predominately in-
fluenced by 20q DNA copy number status rather than being
generally increased due to tumor progression.
3.2 Correlation of CSE1L, DIDO1 and RBM39 protein
expression to chromosome 20q gain and adenoma/
carcinoma status
To investigate the correlation between chromosome 20q DNA
copy number status and CSE1L, DIDO1 and RBM39 protein
expression in colorectal adenoma-to-carcinoma progression,
immunohistochemistry was performed on tissue microarrays
containing 82 colorectal adenomas and 82 carcinomas.
CSE1L protein expression was mainly present in the nuclei
of epithelial cells accompanied by a weak cytoplasmic stain-
ing (Fig. 2a). DIDO1 protein expression was exclusively
nuclear and observed in epithelial cells as well as stromal cells
(Fig. 2b). Nuclear protein expression of RBM39 was associ-
ated with a faint cytoplasmic staining (Fig. 2c).
There was no significant difference in epithelial protein
expression of CSE1L, DIDO1 and RBM39 between tumors
with and without chromosome 20q gain (Fig. 3a-c). However,
CSE1L protein expression in epithelial cells was higher in
carcinomas compared to adenomas (p00.001; Fig. 3d). Epi-
thelial protein expression of DIDO1 and RBM39 was ob-
served in the far majority of tumors. More than 80 % of
adenomas stained strongly positive for DIDO1 and more than
90 % of adenomas for RBM39. Therefore, although the per-
centages of carcinomas with strongDIDO1 or RBM39 protein
expression were slightly higher, significant differences could
not be detected for these two proteins (Fig. 3e-f).
4 Discussion
Chromosome 20q is a major factor in colorectal adenoma-
to-carcinoma progression. Genes that drive 20q gain asso-
ciated colorectal adenoma-to-carcinoma progression are be-
lieved to influence cancer processes due to increased DNA,
mRNA and protein expression levels. The 20q amplicon
harbors multiple genes that contribute to CRC carcinogen-
esis as indicated by the large part of the chromosome arm
that is generally amplified in CRC. We recently identified
AURKA and TPX2 as major contributors to 20q gain asso-
ciated CRC progession [9]. In the same study CSE1L, DI-
DO1 and RBM39 were also found to contribute to several
cancer-related biological processes such as cell viability and
anchorage-independent growth. To further explore the role
Fig. 2 Immunohistochemical stainings of CSE1L, DIDO1 and
RBM39. a CSE1L staining was mainly present in the nuclei of epithe-
lial cells accompanied by a weak cytoplasmic staining. Staining inten-
sity was analyzed based on the overall intensity in epithelial cells, and
scored as weak, moderate, or strong. Representative examples of each
category are shown. b DIDO1 staining was exclusively nuclear, and
was observed in epithelial and stromal cells. Nuclear staining intensity
in epithelial cells was scored as weak, moderate or strong. Represen-
tative examples of each category are shown. c RBM39 staining was
observed in epithelial and stromal cells. Nuclear staining of RBM39
was accompanied by a faint cytoplasmic staining. Staining intensity in
epithelial cells was scored as weak, moderate or strong. Due to lack of
weakly stained cores, only representative examples of moderate and
strong staining are shown
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of CSE1L, DIDO1 and RBM39 in colorectal adenoma-to-
carcinoma progression, we here analyzed mRNA and protein
levels of CSE1L, DIDO1 and RBM39 in colorectal adenomas
and carcinomas in relation to 20q DNA copy number status.
4.1 CSE1L
CSE1L was found to affect cell viability and anchorage-
independent growth (Suppl. Fig. 1). Other studies have
reported that CSE1L plays a role in apoptosis, chromosomal
instability, migration, invasion and metastasis in different
cancer types [14–20]. Increased CSE1L DNA copy numbers
(including high level amplifications), mRNA and protein
expression have been reported for CRC and other tumor
types [21–26]. Overexpression of CSE1L has been linked
to tumor progression [26–29]. In support of these published
data the present study, for the first time, demonstrates in-
creased expression of CSE1L mRNA and protein levels in
colorectal carcinomas compared to adenomas. Based on the
functional effects of CSE1L on cancer processes and the
increased mRNA and protein levels in carcinomas com-
pared to adenomas, CSE1L likely contributes to colon tumor
progression. The correlation of CSE1L (20q) DNA copy
number status with mRNA expression levels implies that
transcription of CSE1L mRNA is influenced by chromo-
some 20q gain. Nevertheless, protein expression of CSE1L
neither correlates with 20q DNA copy number status nor
with mRNA expression levels (Suppl. Fig. 3), implying that
CSE1L protein levels are subject to post-transcriptional
regulation in a 20q gain-independent manner. Because CSE1L
protein expression does not correlate with chromosome 20q
gain status, CSE1L is likely a passenger rather than a driver
gene of chromosome 20q gain-associated adenoma-to-
carcinoma progression.
CSE1L (chromosome segregation 1-like, also known as
Cellular Apoptosis Susceptibility—CAS – ) is a nuclear
transport factor that contributes to protein transport from
the cytoplasm to the nucleus and vice versa. This proces is
important for normal cell function [30]. Proteins that contain
a nuclear localization signal form a complex with importin-
α in the cytoplasm. Subsequent binding of importin-β
results in translocation of the complex to the nucleus, where
the complex dissociates. Importin-β is recycled to the cyto-
plasm by RanGTP, whereas recycling of importin-α is me-
diated by CSE1L [31, 32]. The effect of CSE1L on tumor
progression can be explained by its role in nuclear transport
which requires nuclear localization of CSE1L [16]. The
immunohistochemical stainings show this localization in
colorectal tumors. Overexpression of CSE1L results in con-
stitutive binding to importin-α, causing depletion of free
importin-α which is necessary for nuclear import of proteins
[30]. Aberrant expression of CSE1L may therefore cause
mislocalization of cellular proteins, which can contribute to
tumor development [16, 30]. Interfering with protein func-
tion by sequestering in cellular compartments has for exam-
ple been described to contribute to the functional
inactivation of the tumor suppressor gene TP53 [33]. Weak
CSE1L protein expression was observed in the cytoplasm of
colorectal adenoma and carcinoma samples with staining
levels that were directly correlated to its nuclear staining
Fig. 3 Correlation of CSE1L,
DIDO1 and RBM39 protein
expression with 20q DNA copy
number and adenoma/
carcinoma status. CSE1L a,
DIDO1 b and RBM39 c protein
expression levels in tumors
without and with 20q gain.
CSE1L d, DIDO1 e and
RBM39 f protein expression
levels in human colorectal
adenoma and carcinoma tissues.
P-values were determined using
the Chi-Square test
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levels. Several papers emphasize (vesicular) cytoplasmic
staining of CSE1L and propose a role for CSE1L in vesicle
translocation and protein secretion [34–36]. Proteomics
analysis of cell surface and secretomes of CRC cell lines
supports the presence of CSE1L protein associated with
plasma membranes and secreted microvesicles (supplemen-
tary data in de Wit et al. [11] and Fijneman et al., [37]).
Cytoplasmic staining has also been described to be caused
by the association of CSE1L to microtubules. Microtubule-
bound CSE1L may be an inactive reservoir of CSE1L or
may have a specific biological function during mitosis; e.g.
in chromosome segregation, as the name indicates [38].
Chromosome segregation is a delicate process which can
result in chromosomal aberrations when deregulated. A role
for CSE1L in this process is in agreement with the deficien-
cy in chromosome segregation observed in yeast cells with
CSE1L mutations [18]. Other genes that contribute to chro-
mosomal instability (e.g. AURKA and TPX2) have been
described as playing a major role in colorectal adenoma-
to-carcinoma progression [9, 39].
4.2 DIDO1
In our previous studies, downmodulation of DIDO1 resulted in
reduced anchorage-independent growth (Suppl. Fig.1). DIDO1
mRNA expression correlated with DNA copy number and
chromosome 20q gain status (Fig. 1), which indicates that
elevated DIDO1 expression is induced by gain of the 20q
amplicon. However, no differences could be detected for DI-
DO1 protein expression between tumors with and without
chromosome 20q gain. Such lack of observed variation in
protein expression may be a technical issue. Tumors without
20q gain, which have a relatively low DIDO1 mRNA expres-
sion compared to tumors with 20q gain, already showed quite
strong DIDO1 protein expression. Since immunohistochemistry
is not a stoichiometric technique stainings can only be quantified
within a restricted window of protein expression, upon which
further increase in protein expression will not become visible as
more intense staining. Therefore, the present study does not
support a role for DIDO1 as a ‘driver’ gene for adenoma-to-
carcinoma progression, but rather suggests that increased DI-
DO1 (mRNA) expression in 20q gain tumors results from a
‘passenger’ effect due to its localization on the 20q amplicon.
The putative functional role of DIDO1 in tumor progres-
sion is not quite clear.DIDO1 (death inducer-obligator 1) is an
early apoptosis regulator protein that has been described as a
tumor suppressor gene in hematological myeloid neoplasms.
Upon apoptosis induction, cytoplasmic DIDO1 translocates to
the nucleus to induce caspase levels and activity [40]. Down-
modulation of DIDO1 mRNA expression, however, did not
change cell viability in CRC cell lines upon 5FU-induced
cytotoxicity, arguing against a role for DIDO1 in apoptosis
induction in CRC cells. Disruption of DIDO1 has been
reported to result in chromosomal instability by a defective
mitotic checkpoint [41], while overexpression of DIDO1 also
induces chromosomal instability as observed by asymmetric
divisions leading to the occurrence of lagging chromosomes
[42]. Like DIDO1, inhibition of the expression of other genes
with a role in chromosomal instability, such as AURKA and
TPX2, also reduced anchorage-independent growth [9].
4.3 RBM39
Downmodulation of RBM39 expression affected cell viability
in CRC cell lines (Suppl. Fig. 1). Similar to DIDO1, RBM39
mRNA expression correlated with DNA copy number and
chromosome 20q gain status whereas no differences could be
detected in protein expression between tumors with and with-
out chromosome 20q gain. RBM39mRNA and protein expres-
sion was also not different between adenomas and carcinomas.
Thus, RBM39 mRNA expression is increased due to 20q gain
and could play a role in 20q gain associated tumor progression.
However, the present study does not support a role for RBM39
as a ‘driver’ gene for adenoma-to-carcinoma progression, rath-
er suggests that increased RBM39 (mRNA) expression in 20q
gain tumors results from a ‘passenger’ effect due to its local-
ization on the 20q amplicon.
RBM39 (RNA binding motif protein 39, also known as
CAPER alpha) is a transcriptional coactivator that stimulates
transcription mediated by the progesteron and estrogen steroid
hormone receptors. In addition, RBM39 contributes to alter-
native splicing, which is an important mechanism to create
mRNA, protein and functional diversity by modulation of
processing of pre-mRNAs [43, 44]. Alterations in the activity
of proteins involved in alternative splicing have been de-
scribed to contribute to tumor development and progression,
e.g. for AURKA and TPX2 [45–47]. RBM39 has been de-
scribed to be overexpressed in small-cell lung cancer and
breast cancer [48, 49]. In breast cancer a shift in RBM39
expression was observed from the cytoplasm to the nucleus
during transition from pre-malignancy to carcinoma in situ
[49]. Such a shift in subcellular localization of RBM39 protein
was not observed for the transition of colorectal adenomas
into carcinomas in our experiments, since pre-malignant ade-
nomas already showed strong nuclear staining.
4.4 Summary
In conclusion, CSE1L, DIDO1 and RBM39 can influence
tumor progression by their functional role in various cancer
processes. However, despite their significant correlation be-
tween DNA copy number status and mRNA expression lev-
els, lack of correlation to protein expression levels does not
support these genes as ‘drivers’ for 20q gain associated
adenoma-to-carcinoma progression. Instead, their increased
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mRNA expression appears to be a ‘passenger’ effect due to
their localization on the 20q gain amplicon.
5 Declarations
Collection, storage, and use of tissue and patient data were
performed in agreement with the ‘Code for Proper Second-
ary Use of Human Tissue in the Netherlands’, in compliance
with national and institutional ethical regulations. The
authors declare that they have no conflict of interest.
Acknowledgements This study was financially supported by the
Cancer Center Amsterdam and by an Aegon International Scholarship
in Oncology
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M.J. Thun, Cancer
statistics, 2009. CA Cancer J. Clin. 59, 225 (2009)
2. H. Shinya, W.I. Wolff, Morphology, anatomic distribution and
cancer potential of colonic polyps. Ann. Surg. 190, 679 (1979)
3. H. Rajagopalan, C. Lengauer, Aneuploidy and cancer. Nature 432,
338 (2004)
4. A. Esquela-Kerscher, F.J. Slack, Oncomirs—microRNAs with a
role in cancer. Nat. Rev. Cancer 6, 259 (2006)
5. A.H. Sillars-Hardebol, B. Carvalho,M. van Engeland, R.J. Fijneman,
G.A. Meijer, The adenoma hunt in colorectal cancer screening:
defining the target. J. Pathol. 226, 1 (2012)
6. P.M. De Angelis, O.P. Clausen, A. Schjolberg, T. Stokke, Chro-
mosomal gains and losses in primary colorectal carcinomas
detected by CGH and their associations with tumour DNA ploidy,
genotypes and phenotypes. Br. J. Cancer 80, 526 (1999)
7. B. Carvalho, C. Postma, S. Mongera, E. Hopmans, S. Diskin, M.A.
van de Wiel, W. van Criekinge, O. Thas, A. Matthai, M.A. Cuesta,
J.S. Terhaar Sive Droste, M. Craanen, E. Schrock, B. Ylstra, G.A.
Meijer, Multiple putative oncogenes at the chromosome 20q
amplicon contribute to colorectal adenoma to carcinoma progres-
sion. Gut 58, 79 (2009)
8. C. Postma, S. Terwischa, M.A. Hermsen, J.R. van der Sijp, G.A.
Meijer, Gain of chromosome 20q is an indicator of poor prognosis
in colorectal cancer. Cell. Oncol. 29, 73 (2007)
9. A.H. Sillars-Hardebol, B. Carvalho, M. Tijssen, J.A. Belien, M. de
Wit, P.M. Delis-van Diemen, F. Ponten, M.A. van de Wiel, R.J.
Fijneman, G.A. Meijer, TPX2 and AURKA promote 20q
amplicon-driven colorectal adenoma to carcinoma progression.
Gut doi:10.1136/gutjnl-2011-301153 (Epub ahead of print)
10. P. Platzer, M.B. Upender, K. Wilson, J. Willis, J. Lutterbaugh, A.
Nosrati, J.K. Willson, D. Mack, T. Ried, S. Markowitz, Silence
of chromosomal amplifications in colon cancer. Cancer Res. 62,
1134 (2002)
11. M. de Wit, C.R. Jimenez, B. Carvalho, J.A. Belien, P.M. Delis-van
Diemen, S. Mongera, S.R. Piersma, M. Vikas, S. Navani, F.
Ponten, G.A. Meijer, R.J. Fijneman, Cell surface proteomics iden-
tifies glucose transporter type 1 and prion protein as candidate
biomarkers for colorectal adenoma-to-carcinoma progression. Gut
61, 855 (2012)
12. M. Uhlen, E. Bjorling, C. Agaton, C.A. Szigyarto, B. Amini, E.
Andersen, A.C. Andersson, P. Angelidou, A. Asplund, C.
Asplund, L. Berglund, K. Bergstrom, H. Brumer, D. Cerjan, M.
Ekstrom, A. Elobeid, C. Eriksson, L. Fagerberg, R. Falk, J. Fall,
M. Forsberg, M.G. Bjorklund, K. Gumbel, A. Halimi, I. Hallin, C.
Hamsten, M. Hansson, M. Hedhammar, G. Hercules, C. Kampf, K.
Larsson, M. Lindskog, W. Lodewyckx, J. Lund, J. Lundeberg, K.
Magnusson, E. Malm, P. Nilsson, J. Odling, P. Oksvold, I. Olsson,
E. Oster, J. Ottosson, L. Paavilainen, A. Persson, R. Rimini, J.
Rockberg, M. Runeson, A. Sivertsson, A. Skollermo, J. Steen, M.
Stenvall, F. Sterky, S. Stromberg, M. Sundberg, H. Tegel, S.
Tourle, E. Wahlund, A. Walden, J. Wan, H. Wernerus, J. Westberg,
K. Wester, U. Wrethagen, L.L. Xu, S. Hober, F. Ponten, A human
protein atlas for normal and cancer tissues based on antibody
proteomics. Mol. Cell Proteomics. 4, 1920 (2005)
13. M. Uhlen, P. Oksvold, L. Fagerberg, E. Lundberg, K. Jonasson, M.
Forsberg, M. Zwahlen, C. Kampf, K. Wester, S. Hober, H. Werne-
rus, L. Bjorling, F. Ponten, Towards a knowledge-based Human
Protein Atlas. Nat. Biotechnol. 28, 1248 (2010)
14. U. Brinkmann, E. Brinkmann, M. Gallo, I. Pastan, Cloning and
characterization of a cellular apoptosis susceptibility gene, the
human homologue to the yeast chromosome segregation gene
CSE1. Proc. Natl. Acad. Sci. U. S. A. 92, 10427 (1995)
15. U. Brinkmann, E. Brinkmann, M. Gallo, U. Scherf, I. Pastan, Role
of CAS, a human homologue to the yeast chromosome segregation
gene CSE1, in toxin and tumor necrosis factor mediated apoptosis.
Biochemistry 35, 6891 (1996)
16. U. Brinkmann, CAS, the human homologue of the yeast
chromosome-segregation gene CSE1, in proliferation, apoptosis,
and cancer. Am. J. Hum. Genet. 62, 509 (1998)
17. A. Wellmann, L. Krenacs, T. Fest, U. Scherf, I. Pastan, M. Raffeld,
U. Brinkmann, Localization of the cell proliferation and apoptosis-
associated CAS protein in lymphoid neoplasms. Am. J. Pathol.
150, 25 (1997)
18. Z. Xiao, J.T. McGrew, A.J. Schroeder, M. Fitzgerald-Hayes, CSE1
and CSE2, two new genes required for accurate mitotic chromo-
some segregation in Saccharomyces cerevisiae. Mol. Cell. Biol.
13, 4691 (1993)
19. C.F. Liao, S.F. Luo, L.T. Li, C.Y. Lin, Y.C. Chen, M.C. Jiang,
CSE1L/CAS, the cellular apoptosis susceptibility protein, enhan-
ces invasion and metastasis but not proliferation of cancer cells. J.
Exp. Clin. Cancer Res. 27, 15 (2008)
20. C.J. Tai, S.C. Shen, W.R. Lee, C.F. Liao, W.P. Deng, H.Y. Chiou,
C.I. Hsieh, J.N. Tung, C.S. Chen, J.F. Chiou, L.T. Li, C.Y. Lin,
C.H. Hsu, M.C. Jiang, Increased cellular apoptosis susceptibility
(CSE1L/CAS) protein expression promotes protrusion extension
and enhances migration of MCF-7 breast cancer cells. Exp. Cell
Res. 316, 2969 (2010)
21. U. Brinkmann, M. Gallo, M.H. Polymeropoulos, I. Pastan, The
human CAS (cellular apoptosis susceptibility) gene mapping on
chromosome 20q13 is amplified in BT474 breast cancer cells and
part of aberrant chromosomes in breast and colon cancer cell lines.
Genome Res. 6, 187 (1996)
22. A.B. Hui, K.W. Lo, P.M. Teo, K.F. To, D.P. Huang, Genome wide
detection of oncogene amplifications in nasopharyngeal carcinoma
by array based comparative genomic hybridization. Int. J. Oncol.
20, 467 (2002)
23. C.Y. Tong, A.B. Hui, X.L. Yin, J.C. Pang, X.L. Zhu, W.S. Poon,
H.K. Ng, Detection of oncogene amplifications in medulloblasto-
mas by comparative genomic hybridization and array-based com-
parative genomic hybridization. J. Neurosurg. 100, 187 (2004)
24. H. Brustmann, Expression of cellular apoptosis susceptibility pro-
tein in serous ovarian carcinoma: a clinicopathologic and immu-
nohistochemical study. Gynecol. Oncol. 92, 268 (2004)
CSE1L, DIDO1 and RBM39 in colorectal tumor progression 299
25. K. Shiraki, K. Fujikawa, K. Sugimoto, T. Ito, T. Yamanaka, M.
Suzuki, K. Yoneda, K. Sugimoto, K. Takase, T. Nakano, Cellular
apoptosis susceptibility protein and proliferation in human hepa-
tocellular carcinoma. Int. J. Mol. Med. 18, 77 (2006)
26. I.M. Seiden-Long, K.R. Brown,W. Shih, D.A.Wigle, N. Radulovich,
I. Jurisica, M.S. Tsao, Transcriptional targets of hepatocyte growth
factor signaling and Ki-ras oncogene activation in colorectal cancer.
Oncogene 25, 91 (2006)
27. A. Wellmann, P. Flemming, P. Behrens, K. Wuppermann, H. Lang,
K. Oldhafer, I. Pastan, U. Brinkmann, High expression of the
proliferation and apoptosis associated CSE1L/CAS gene in hepa-
titis and liver neoplasms: Correlation with tumor progression. Int.
J. Mol. Med. 7, 489 (2001)
28. P. Behrens, U. Brinkmann, F. Fogt, N. Wernert, A. Wellmann, Impli-
cation of the proliferation and apoptosis associated CSE1L/CAS gene
for breast cancer development. Anticancer. Res. 21, 2413 (2001)
29. G. Peiro, J. Diebold, G.B. Baretton, R. Kimmig, U. Lohrs, Cellular
apoptosis susceptibility gene expression in endometrial carcinoma:
Correlation with Bcl-2, Bax, and caspase-3 expression and out-
come. Int. J. Gynecol. Pathol. 20, 359 (2001)
30. T.R. Kau, J.C. Way, P.A. Silver, Nuclear transport and cancer:
From mechanism to intervention. Nat. Rev. Cancer 4, 106 (2004)
31. U. Kutay, F.R. Bischoff, S. Kostka, R. Kraft, D. Gorlich, Export of
importin alpha from the nucleus is mediated by a specific nuclear
transport factor. Cell 90, 1061 (1997)
32. K.S. Ullman, M.A. Powers, D.J. Forbes, Nuclear export receptors:
From importin to exportin. Cell 90, 967 (1997)
33. K.M. Ryan, A.C. Phillips, K.H. Vousden, Regulation and
function of the p53 tumor suppressor protein. Curr. Opin.
Cell Biol. 13, 332 (2001)
34. W.C. Uen, C.J. Tai, S.C. Shen, W.R. Lee, T.Y. Tsao, W.P. Deng,
H.Y. Chiou, C.H. Hsu, C.I. Hsieh, C.F. Liao, M.C. Jiang, Differ-
ential distributions of CSE1L/CAS and E-cadherin in the polarized
and non-polarized epithelial glands of neoplastic colorectal epithe-
lium. J. Mol. Histol. 41, 259 (2010)
35. C.S. Stella Tsai, H.C. Chen, J.N. Tung, S.S. Tsou, T.Y. Tsao, C.F.
Liao, Y.C. Chen, C.Y. Yeh, K.T. Yeh, M.C. Jiang, Serum cellular
apoptosis susceptibility protein is a potential prognostic marker for
metastatic colorectal cancer. Am. J. Pathol. 176, 1619 (2010)
36. T.Y. Tsao, C.S. Tsai, J.N. Tung, S.L. Chen, C.H. Yue, C.F. Liao,
C.C. Wang, M.C. Jiang, Function of CSE1L/CAS in the secretion
of HT-29 human colorectal cells and its expression in human
colon. Mol. Cell. Biochem. 327, 163 (2009)
37. R.J. Fijneman, M. de Wit, M. Pourghiasian, S.R. Piersma, T.V.
Pham, M.O. Warmoes, M. Lavaei, C. Piso, F. Smit, P.M. Delis-van
Diemen, S.T. van Turenhout, J.S.Terhaar sive Droste, C.J. Mulder,
M.A. Blankenstein, E.C. Robanus-Maandag, R. Smits, R. Fodde,
V.W. van Hinsbergh, G.A. Meijer, C.R. Jimenez, Proximal fluid
proteome profiling of mouse colon tumors reveals biomarkers for
early diagnosis of human colorectal cancer. Clin. Cancer Res. 18,
2613 (2012)
38. U. Scherf, I. Pastan, M.C. Willingham, U. Brinkmann, The human
CAS protein which is homologous to the CSE1 yeast chromosome
segregation gene product is associated with microtubules and
mitotic spindle. Proc. Natl. Acad. Sci. U. S. A. 93, 2670 (1996)
39. A.H. Sillars-Hardebol, B. Carvalho, M. de Wit, C. Postma, P.M.
Delis-van Diemen, S. Mongera, B. Ylstra, M.A. van de Wiel, G.A.
Meijer, R.J. Fijneman, Identification of key genes for carcinogenic
pathways associated with colorectal adenoma-to-carcinoma pro-
gression. Tumour. Biol. 31, 89 (2010)
40. D. Garcia-Domingo, D. Ramirez, G. Gonzalez de Buitrago, A.
Martinez, Death inducer-obliterator 1 triggers apoptosis after nu-
clear translocation and caspase upregulation. Mol. Cell. Biol. 23,
3216 (2003)
41. V. Trachana, K.H. vanWely, A.A. Guerrero, A. Futterer, A.Martinez,
Dido disruption leads to centrosome amplification andmitotic check-
point defects compromising chromosome stability. Proc. Natl. Acad.
Sci. U. S. A. 104, 2691 (2007)
42. A.M. Rojas, L. Sanchez-Pulido, A. Futterer, K.H. van Wely, A.
Martinez, A. Valencia, Death inducer obliterator protein 1 in the
context of DNA regulation. Sequence analyses of distant homo-
logues point to a novel functional role. FEBS J. 272, 3505 (2005)
43. D.J. Jung, S.Y. Na, D.S. Na, J.W. Lee, Molecular cloning and
characterization of CAPER, a novel coactivator of activating
protein-1 and estrogen receptors. J. Biol. Chem. 277, 1229 (2002)
44. D.H. Dowhan, E.P. Hong, D. Auboeuf, A.P. Dennis, M.M. Wilson,
S.M. Berget, B.W. O’Malley, Steroid hormone receptor coactiva-
tion and alternative RNA splicing by U2AF65-related proteins
CAPERalpha and CAPERbeta. Mol. Cell 17, 429 (2005)
45. A. Srebrow, A.R. Kornblihtt, The connection between splicing and
cancer. J. Cell Sci. 119, 2635 (2006)
46. J.P. Venables, Unbalanced alternative splicing and its significance
in cancer. Bioessays 28, 378 (2006)
47. M.J. Moore, Q. Wang, C.J. Kennedy, P.A. Silver, An alternative
splicing network links cell-cycle control to apoptosis. Cell 142,
625 (2010)
48. C.S. Bangur, A. Switzer, L. Fan, M.J. Marton, M.R. Meyer, T.
Wang, Identification of genes over-expressed in small cell lung
carcinoma using suppression subtractive hybridization and cDNA
microarray expression analysis. Oncogene 21, 3814 (2002)
49. I. Mercier, M.C. Casimiro, J. Zhou, C. Wang, C. Plymire, K.G.
Bryant, K.M. Daumer, F. Sotgia, G. Bonuccelli, A.K. Witkiewicz,
J. Lin, T.H. Tran, J. Milliman, P.G. Frank, J.F. Jasmin, H. Rui, R.G.
Pestell, M.P. Lisanti, Genetic ablation of caveolin-1 drives
estrogen-hypersensitivity and the development of DCIS-like mam-
mary lesions. Am. J. Pathol. 174, 1172 (2009)
300 A.H. Sillars-Hardebol et al.
